Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04060394
Recruitment Status : Recruiting
First Posted : August 19, 2019
Last Update Posted : April 3, 2020
Sponsor:
Information provided by (Responsible Party):
Laekna Limited

Brief Summary:
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC) patients who have progressed/drug resistant following prior standard care treatments of any anti-androgen. This study intends to identify the most appropriate combined doses of LAE001/prednisone and afuresertib in m-CRPC patients who have progressive disease or are intolerant of 2 prior standard treatments of any anti-androgen or anti-androgen treatment plus chemotherapy.

Condition or disease Intervention/treatment Phase
Metastatic Castration-resistant Prostate Cancer Drug: Phase I and Phase II: LAE001/prednisone + afuresertib Phase 1 Phase 2

Detailed Description:

The Phase I part of this study will perform a dose-escalation to identify the recommended Phase II dose of LAE001/prednisone plus afuresertib in m-CRPC patients.

In the Phase II part of this study, the anti-tumor efficacy of LAE001/prednisone plus afuresertib and of afuresertib alone will be assessed in m-CRPC patients with Phosphatase and tensin homolog (PTEN) loss who have progressed on, or who are intolerant of, 2 prior standard treatments of any anti-androgen or one anti-androgen treatment plus one of the chemotherapy from docetaxel or cabazitaxel. These study results will provide preliminary efficacy and safety information of the combination of LAE001/prednisone plus afuresertib and afuresertib alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase 1 Dose Escalation to determine Recommended Phase II Dose (RP2D) of LAE001/Prednisone plus Afuresertib in m-CRPC patients. Once RP2D is determined, Phase II will evaluate LAE001/Prednisone plus Afuresertib vs Afuresertib monotherapy in m-CRPC patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Actual Study Start Date : September 13, 2019
Estimated Primary Completion Date : September 1, 2021
Estimated Study Completion Date : October 30, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Prednisone

Arm Intervention/treatment
Experimental: Phase I Cohort 1
LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib

Experimental: Phase I Cohort 2
LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib

Experimental: Phase I Cohort 3
LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib

Experimental: Phase I Cohort 4
LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib

Experimental: Phase II Arm 1
LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib

Experimental: Phase II Arm 2
Afuresertib 150 mg
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
Other Name: Phase II: Afuresertib




Primary Outcome Measures :
  1. Phase II: Radiological progression free survival (rPFS) based on change in tumor per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment.

  2. Phase I: Demonstrate safety and tolerability of LAE001/prednisone and afuresertib as combination therapy. [ Time Frame: Through study completion for an average of 12 months ]
    Frequency and severity of AEs.

  3. Phase II: Radiological progression free survival (rPFS) based changes per Prostate Cancer Working Group 3 (PCWG3) [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment.


Secondary Outcome Measures :
  1. Phase II: Overall Response Rate (ORR) based tumor changes per RECIST 1.1 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessments and death from any cause.

  2. Phase II: Overall Response Rate (ORR) based tumor changes per PCWG3 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessments and death from any cause.

  3. Phase II: Duration of Response (DOR) based on tumor changes per RECIST 1.1 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  4. Phase I: Duration of Response (DOR) based on tumor changes per RECIST 1.1 [ Time Frame: At the end of the 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  5. Phase II: Duration of Response (DOR) based on tumor changes per PCWG3 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  6. Phase I: Duration of Response (DOR) based on tumor changes per PCWG3 [ Time Frame: At the end of the 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  7. Phase II: Disease Control Rate (DCR) based on tumor changes per RECIST 1.1 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  8. Phase II: Disease Control Rate (DCR) based on tumor changes per PCWG3 [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  9. Phase II: Overall Survival (OS) [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment and death.

  10. Phase II: Changes in Prostate Specific Antigen (PSA) levels [ Time Frame: End of Treatment as compared to baseline ]
    Analysis of blood samples to be drawn at baseline and end of treatment

  11. Phase I: Changes in Prostate Specific Antigen (PSA) levels [ Time Frame: Day 1 Cycle 2 (each cycle is 28 days) and all subsequent cycle and End of Treatment for an avergae of 12 months as compared to baseline ]
    Analysis of blood samples to be drawn at baseline and end of treatment

  12. Phase II: PSA response [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    A >/=50% reduction in PSA from baseline

  13. Phase I: PSA response [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    A >/=50% reduction in PSA from baseline

  14. Phase II: Secondary PSA response [ Time Frame: Baseline to>/=12 weeks after study treatment; confirmed 4 weeks later ]
    A >/=30% reduction

  15. Phase I: Secondary PSA response [ Time Frame: Baseline to>/=12 weeks after study treatment; confirmed 4 weeks later ]
    A >/=30% reduction

  16. Phase II: Best PSA response [ Time Frame: Through study completion for an avergae of 12 months ]
    According to PCWG3

  17. Phase I: Best PSA response [ Time Frame: Through study completion for an average of 12 months ]
    According to PCWG3

  18. Phase II: Time to PSA progression [ Time Frame: Through study completion for an average of 12 months ]
    According to PCWG3

  19. Phase I: Time to PSA progression [ Time Frame: Through study completion for an average of 12 months ]
    According to PCWG3

  20. Phase II: % patients with PSA progression or death from any cause [ Time Frame: At 12 weeks from start of study treatment ]
    Patients with PSA progression or have died 12 weeks after treatment

  21. Phase II: Frequency and severity of AEs [ Time Frame: Through study completion for an average of 12 months ]
    Findings on physical examination, ECGs, vital signs and laboratory results based on CTCAE v5.0

  22. Phase I: Evaluate PK characteristics of study drug in combination treatment [ Time Frame: Cycle 1 (each cycle is 28 days) Day 1 and Cycle 1 Day 15 ]
    Assess PK parameters as various timepoints

  23. Phase I: Describe pharmacodynamics of study drugs [ Time Frame: Cycle 1 (each cycle is 28 days) Days 1,8,15 and 22 and Day 1 of subsequent cycles ]
    Based on changes in blood levels on adrenal hormone and testosterone levels

  24. Phase I: Radiographic tumor response based on Prostate Cancer Working Group 3 (PCWG3) [ Time Frame: At the end of each 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment.

  25. Phase I: Radiographic tumor response based on RECIST 1.1 [ Time Frame: At the end of each 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment ]
    Based on investigator reviewed radiographic tumor assessment.


Other Outcome Measures:
  1. Phase I: Relationship between PSA levels and testosterone levels [ Time Frame: Cycle 1 (each cycle is 28 days) Days 1,8,15 and 22 and Day 1 of subsequent cycles ]
    Correlation between testosterone decreasing and PSA level changes

  2. Phase I: Explore correlation between anti-tumor activity and patient's PTEN status [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Anti-tumor activity (rPFS, DOR, ORR, PSA) in patients with PTEN loss

  3. Phase I: Explore correlation between anti-tumor activity and patient's BRCA mutation status [ Time Frame: At the end of each 28 day treatment cycle and within 15 days of last treatment ]
    Anti-tumor activity (rPFS, DOR, ORR, PSA) in patients with BRCA Mutations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Prostate cancer
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients, males ≥18 years of age, must be able to provide written informed consent.
  2. Patients must have documented histological or cytological evidence of adenocarcinoma of the prostate (excluding neuroendocrine differentiation or small cell histology).
  3. Patients must have radiographic evidence of metastatic disease based on RECIST 1.1 within the 28 days before enrollment.
  4. Patients are able to provide tumor biopsy samples for PTEN immunohistochemical (IHC) staining. A valid PTEN IHC result must be collected within 4 months of screening visit or from a fresh biopsy sample during screening visit. The PTEN ICH results should be either performed or confirmed, if there is a previous PTEN ICH result, by central laboratory testing (participants with an "invalid" or "failed" PTEN IHC result are not permitted to be enrolled in Phase II study but allowed to participate in Phase I study).
  5. Patients must have progressive disease based on the PCWG3 criteria:

    • Patients who progressed based solely on total PSA rising, should have had a sequence of rising values on 3 consecutive occasions of at least 1-week intervals (if the third measurement is not greater than the second measurement, a fourth measurement at least a week apart must be taken and must be greater than the second measurement) and should have 2.0 ng/mL minimum level for entry.
    • Patients who have documented disease progression per RECIST 1.1 are eligible independent of PSA.
    • Patients with bone only progression according to PCWG3 (ie, bone scan showing appearance of ≥2 new lesions).

    Note: Patients must have had a prior PSA response, followed by documented PSA progression on prior hormone treatment.

  6. Patients must have castration levels of testosterone (<50 ng/dL or 1.7 nmol/L). Note: Patients must have undergone androgen deprivation therapy (ADT), such as orchiectomy, or have been on Luteinizing Hormone Releasing Hormone (LHRH) agonists or antagonists, for at least 3 months prior to study enrollment. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.
  7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
  8. Patients must have adequate hematopoietic function by local laboratory within the 28 days before enrollment, as evidenced by:

    • Absolute neutrophil count ≥1,500/μL
    • Platelet count ≥75,000/μL
    • Hemoglobin ≥9 g/dL
  9. Total serum bilirubin ≤1.5 × Upper Limit of Normal (ULN) within the 28 days before enrollment (in patients with known Gilbert's syndrome, total bilirubin ≤3 × ULN with direct bilirubin ≤1.5 × ULN).
  10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN except for patients with tumor involvement of the liver who must have AST and ALT ≤5 × ULN within the 28 days before enrollment.
  11. Patients must have adequate renal function as evidenced by a serum creatinine of ≤1.5 × the ULN for the reference laboratory or creatinine clearance ≥50 mL/min within the 28 days before enrollment (calculated from Cockcroft-Gault formula or 24-hour urine collection).
  12. Serum potassium ≥3.5 mmol/L and < ULN within the 28 days before enrollment.
  13. Fasting glucose ≤120 mg/dL or ≤6.7 mmol/L; glycosylated hemoglobin ≤8% within the 28 days before enrollment.
  14. Patients who have mCRPC progressed or are intolerant after receiving 2 prior treatments of any anti-androgen (such as abiraterone, enzalutamide, apalutamide, or any other Adrenergic Agonist (AR) antagonists that are approved later), or one of the above anti-androgen treatments plus one of the chemotherapies from docetaxel or cabazitaxel. Patients must have at least 3 weeks of treatment of any antiandrogen and/or completed at least 4 Cycles of docetaxel or cabazitaxel treatment before their screening visit.
  15. Concomitant use of bisphosphonates and other bone supportive agents is allowed if the dose and renal function have been stable for at least 12 weeks before enrollment and no related ≥Grade 2 side effects are present for at least 4 weeks prior to study drug treatment.

    The minimum washout period is 4 weeks for prostate cancer therapy (cytotoxic, biologic, other therapies), and 6 weeks for antiandrogens bicalutamide and MDV3100 before enrollment, starting from the day the therapies were stopped.

  16. Patients with a female partner of childbearing potential must agree to use condoms plus an additional contraceptive method to avoid conception until the end of relevant systemic exposure plus 90 days following the Clinical Trial Facilitation Group contraception guideline from September 2014.
  17. Patient should be able to swallow and retain oral medication and should not have any known gastrointestinal diseases that may interfere with drug absorption.
  18. Life expectancy of at least 6 months.

Exclusion Criteria:

  • 1. Major surgery within 28 days before study treatment and/or have not recovered fully from the adverse effects of any major surgical procedures before study treatment.

    2. Patients that received other second-line Androgen Deprivation Therapy (ADT) (including but not limited to ketoconazole and amino glutethimide) within 6 weeks before enrollment.

    3. Patients who have completed sipuleucel-T (Provenge®) treatment within 3 months of enrollment.

    4. Patients who have received antiandrogens such as flutamide (EULEXIN®), bicalutamide (CASODEX®), or nilutamide (NILANDRON®) for >3 months must be off treatment for 6 weeks prior to enrollment and should demonstrate a continued rise in PSA after withdrawal.

    5. Patients on 5-alpha reductase inhibitors such as finasteride (PROSCAR®, PROPECIA®), or dutasteride (AVODART®) must stop medication at least 3 months prior to enrollment.

    6. Patients who have received Radium Ra 223 dichloride (XOFIGO®) or Samarium Sm 153 lexidronam (QUADRAMET®) must be off therapy for at least 3 months prior to enrollment.

    7. Patients that are currently receiving increasing or chronic treatment (>5 days) with corticosteroids or another immunosuppressive agent, other than daily use of up to 10 mg prednisone (or equivalent) or low-dose steroid for the control of nausea and vomiting, topical steroid, or inhaled steroid use.

    8. Patients who require potassium-wasting diuretics. 9. Patients who have received any investigational agent beyond those indicated for the treatment of prostate cancer within 5 half-lives of the agent; if the half-life of the agent is not known, the patients must be off investigational therapy for 4 weeks prior to enrollment.

    10. Patients who have received palliative and other radiotherapy within 4 weeks of study enrollment.

    11. Patients with symptomatic or known central nervous system metastases from prostate cancer or who are at high risk for spinal cord compression, per investigator's judgment.

    12. Patients with a history of hypothalamus, pituitary or adrenal insufficiency.

    13. Patients with diabetes mellitus that require insulin at study enrollment. 14. History of another primary malignancy that is currently clinically significant or currently requires active intervention.

    15. Inadequately controlled hypertension (eg, systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg) or hypotension (eg, systolic blood pressure ≤80 mmHg or diastolic blood pressure ≤50 mmHg) after up to 3 measurements with at least 5 minutes apart during 28 days before study enrollment.

    16. Patients with active cardiac disease or a history of cardiac dysfunction including any of the following:

  • Severe or unstable angina pectoris or acute coronary syndrome or stroke within 6 months prior to study enrollment.
  • Symptomatic pericarditis.
  • Documented myocardial infarction or arterial thrombotic events within 6 months prior to study enrollment.
  • History of documented congestive heart failure (New York Health Association functional classification III to IV).
  • Documented history of cardiomyopathy.
  • Known left ventricular ejection fraction <50% as determined by multiple gated acquisition scan or echocardiogram within 28 days prior to enrollment.
  • History of clinically significant cardiac arrhythmias, as determined by the investigator.

    17. Patients with a Fridericia-corrected QT (QTcF) interval of >450 msec on the screening electrocardiogram (ECG) (using the QTcF formula), has a short/long QT syndrome, or history of QT prolongation/Torsades de Pointes.

    18. Patients with a history of an active infection (viral, bacterial, or fungal) requiring systemic therapy within 10 days before enrollment, including but not limited to tuberculosis.

    19. Patients who have active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infections.

    20. Patients that are currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP1A (including but not limited: α-Naphthoflavone, Furafylline, Omeprazole, Lansoprazole) and isoenzyme CYP3A (including but not limited: Itraconazole, Ketoconazole, Azamulin, Troleandomycin, Verapamil, Rifampicin). The patients must have discontinued moderate or strong inducers for at least 2 weeks prior to study enrollment and must have discontinued moderate or strong inhibitors for at least 1 week before study enrollment. Spironolactone, Strong bile salt export pump (BSEP) inhibitors, grapefruit juice, herbal medicines such as St. John's wort, Kava, ephedra, gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto and ginseng should be discontinued.

    21. Sexually active males not willing to use a condom during the whole course of the study and for 16 weeks after stopping treatment. Male patients must not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via seminal fluid.

    22. Patients with any other medical, psychiatric, or social condition, including substance abuse, which in the opinion of the investigator, would preclude participation in the study.

    23. Patients with a history of upper gastrointestinal bleeding or peptic disease in the previous 6 months.

    24. Patients have previously received AKT or PI3 kinase pathway or mTOR inhibitors.

    25. Any condition that in the assessment of the investigator renders the patient not suitable for participation in this clinical study protocol


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060394


Contacts
Layout table for location contacts
Contact: Yong Yue 7328502641 yong.yue@laeknatp.com
Contact: Angela Castagna 9085076807 angela.castagna@laeknatp.com

Locations
Layout table for location information
United States, Arizona
Urological Associates of Southern Arizona Recruiting
Tucson, Arizona, United States, 85741
Contact: Curtis Dunshee, MD    520-547-9777    doccd@uasapc.com   
Principal Investigator: Curtis Dunshee, MD         
United States, California
California Cancer Associates for Researh & Excellence, Inc Recruiting
Encinitas, California, United States, 92024
Principal Investigator: Alberto Bessudo, MD         
United States, Connecticut
Eastern Connnecticut Hematology/Oncology Associates Recruiting
Norwich, Connecticut, United States, 06360
Principal Investigator: Dennis Slater, MD         
United States, New York
Associated Medical Professionals of NY Recruiting
Syracuse, New York, United States, 13215
Principal Investigator: Christopher Pieczonka, MD         
United States, Texas
Mary Crowley Cancer Research Centers Recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Ashley Ross, MD         
United States, Washington
Northwest Medical Specialties, PLLC Recruiting
Tacoma, Washington, United States, 98405
Principal Investigator: Jorge Chaves, MD         
Sponsors and Collaborators
Laekna Limited
Investigators
Layout table for investigator information
Study Chair: Yong Yue, MD Laekna Therapeutics
Layout table for additonal information
Responsible Party: Laekna Limited
ClinicalTrials.gov Identifier: NCT04060394    
Other Study ID Numbers: LAE201INT2101
First Posted: August 19, 2019    Key Record Dates
Last Update Posted: April 3, 2020
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents